Integrated Clinical Development Planning for Iron Overload Candidate


An exciting biotechnology company that develops gene therapeutic technology based on RNA wanted to develop a baseline, integrated development plan for a lead iron overload (IO) candidate.  The client was keen to take a data led approach to understand and document the following:

  • Competitor activity, dosing and development status, including relevant input for strategic business development activities and interactions with the regulatory agency
  • Lead target indication(s)
  • Leading countries, KOLs and trialists
  • Protocol design, including baseline patient characteristics, standard of care, outcome measures and inclusion/ exclusion criteria

The Development program should capitalize on the coexistence of 10 patients and maximize ROI


Within three months Phesi successfully delivered to the Board a baseline, fully integrated development plan document covering:

  • Product positioning: TPP and commercial potential, the potential candidate value increasing 5-fold as a result of the analysis
  • Clinical development timelines and implementation planning
  • Regulatory strategy
  • NCD strategy
  • Program timelines, resourcing and budget
  • Leading authorities from a KOL and trialist stand point

Related Posts

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.